NCT03714022View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes

PHASE1CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

April 2, 2019

Study Completion Date

April 2, 2019

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Abatacept

Participants will receive abatacept at a single dose 750 mg as IV infusion.

Trial Locations (2)

33143

Qps-Mra, Llc, South Miami

78744

PPD Development, LP, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY